What is Neogenomics's latest dividend and current dividend yield?

What factors drove the changes in Neogenomics's revenue and profit?

What is Neogenomics's gross profit margin?

Did Neogenomics beat or miss consensus estimates last quarter?

What does Neogenomics do and what are its main business segments?

What is the market's earnings forecast for Neogenomics next quarter?

What is the revenue and EPS growth rate for Neogenomics year over year?

What guidance did Neogenomics's management provide for the next earnings period?

**Key Takeaways:**
- **Revenue Momentum**: 12% YoY growth driven by 24% NGS expansion and 15% clinical volume growth.
- **MRD Breakthrough**: RaDaR ST launch in Q1 2026 targets $30B MRD market, with pharma bookings starting Q4 2025.
- **Operational Efficiency**: LIMS consolidation and sales force expansion to drive 2026+ margin improvement.
- **Strategic Focus**: Community oncology consolidation (80%+ cancer care) and AI-driven MRD innovation.

**【CEO Summary Section】**
- **Revenue Growth**: Total revenue of $188 million, up 12% YoY, driven by 18% clinical revenue growth. NGS revenue grew 24% YoY, accounting for 33% of clinical revenue.
- **Strategic Initiatives**: Secured court ruling to commercialize RaDaR ST MRD assay, launching in Q1 2026. Pathline acquisition on track to accelerate Northeast growth, with integration complete.
- **Customer Experience**: Emphasized fast turnaround times (e.g., 7-day average for PanTracer LBx) and comprehensive oncology menu (over 500 tests) to consolidate community oncology send-out.
- **Guidance**: Reiterated full-year 2025 guidance: $720-726 million revenue, $41-44 million adjusted EBITDA, and $108-116 million net loss.

**【CFO Financial Commentary】**
- **Financial Highlights**: Adjusted EBITDA of $12.2 million (9th consecutive quarter of positive earnings). Operating expenses up 12% YoY due to sales team expansion and Pathline-related costs.
- **Key Metrics**: AUP increased 3% YoY (excluding Pathline), clinical test volumes up 15%. Nonclinical revenue declined 27% YoY, consistent with strategic focus on clinical growth.
- **Cash Position**: $164 million cash on hand, supporting investments in growth and operational efficiency.

**【Q&A Key Highlights】**
- **MRD Growth**: RaDaR ST expected to contribute $30 million+ in 2026, with pharma bookings starting Q4 2025. MRD market $30B+ at 30% CAGR, with Neo targeting 10%+ penetration.
- **LIMS Rollout**: LIMS consolidation to reduce costs and improve workflow efficiency, with benefits materializing in 2026-2027.
- **Sales Force Expansion**: 2025 sales team additions driving 10%+ volume growth, with further expansion planned for 2026.
- **PanTracer LBx**: Launched in Q3, early uptake strong but reimbursement-dependent, with potential 2026 revenue contribution.
- **Pharma Recovery**: Pharma business expected to remain soft in 2026, with recovery in 2027 tied to MRD adoption and new product launches.

NeoGenomics, Inc. (NEO) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: 10% YoY total revenue ($181M), driven by 16% clinical growth despite pharma headwinds.
- **Key Product Delay**: PanTracer liquid biopsy launch delayed 3 months to enhance product profile, targeting <7-day TAT and 500+ gene panel.
- **Strategic Focus**: Community oncology partnerships (e.g., Adaptive Biotechnologies) and NGS/MRD innovation to capture 10%+ annual growth.
- **Financial Health**: $164M cash balance, positive Q2 cash flow, and revised 2025 guidance reflecting pharma risks.
- **Shareholder Action**: Management and directors increased stake, signaling confidence in execution.


**【CEO Summary Section】**
- **Revenue Performance**: Q2 2025 revenue of $181 million, 10% YoY growth, with clinical revenue up 16% (organic growth 13%). NGS revenue grew 23% YoY, despite a 3-month delay in PanTracer liquid biopsy launch.
- **Challenges**: Nonclinical revenue down 26% YoY due to pharma macro headwinds (NIH funding uncertainty, drug pricing pressures). Pharma revenue shortfall expected to widen beyond initial $7 million estimate.
- **Strategic Focus**: 
  - **Customer Experience**: Investing in sales force effectiveness, EPIC integrations, and LIMS consolidation to improve turnaround times.
  - **Community Channel**: Strengthening partnerships (e.g., Adaptive Biotechnologies for MRD testing) to capture 80% of cancer patients treated in community settings.
  - **New Products**: Launching PanTracer liquid biopsy (500+ gene panel with TMB/MSI markers) and advancing next-gen MRD solutions.
- **Long-Range Plan**: Core clinical business expected to grow 10%+ annually, with upside from R&D (MRD, NGS) and business development (lumpy timing).

**【CFO Financial Commentary】**
- **Financial Results**: 
  - GAAP net income: $42 million; Adjusted EBITDA: $10.7 million (down 2% YoY due to Pathline integration costs).
  - Clinical AUP: $461 (2% YoY growth); NGS mix: 32% of clinical revenue.
  - Cash flow: $20 million Q2, ending with $164 million in cash.
- **Revised Guidance**: 
  - Full-year 2025 revenue: $720-726 million (9-10% growth); Adjusted EBITDA: $41-44 million.
  - Pathline impact: $1 million EBITDA drag for remainder of year.
- **Debt Management**: Retired $201 million convertible notes, reducing near-term debt maturities.

**【Q&A Highlights】**
- **PanTracer Launch**: Commercial launch delayed 3 months to refine product profile (lower QNS, <7-day TAT). Adaptive Biotechnologies partnership for MRD testing in pilot phase.
- **Pharma Business**: 2/3 of guidance reduction attributed to pharma macro challenges; Paletrra spatial proteomics platform launched in June but early-stage.
- **Operating Efficiency**: LIMS consolidation and digital pathology investments expected to drive back-half operating leverage.
- **Litigation Update**: RaDaR MRD trial set for October; MolDX bridging study completed, next-gen MRD R&D ongoing.
- **Shareholder Confidence**: Management and directors purchased additional shares, signaling confidence in turnaround.


NeoGenomics, Inc. (NEO) Q2 2025 Earnings Call Transcript

- **Q1 Financial Strength**: $168M revenue (+8% YoY), $7.1M adjusted EBITDA, seventh straight quarter of positive EBITDA.
- **NGS Growth Engine**: 18% NGS revenue growth, five new products driving 22% of clinical revenue.
- **Strategic Acquisitions**: Pathline acquisition to add $12-14M 2025 revenue, expanding Northeast market reach.
- **Innovation Pipeline**: PanTracer LBx liquid biopsy launch Q2, next-gen MRD 2027, and Ultima Genomics partnership for advanced sequencing.
- **Financial Discipline**: 47% adjusted gross margin, $358M cash, and 2025 guidance raised to $747-759M revenue.

**【CEO Summary Section】**
- NEO's Q1 2025 revenue reached $168 million, up 8% YoY, with adjusted EBITDA of $7.1 million, marking the seventh consecutive quarter of positive adjusted EBITDA.
- Strategic focus on innovation through R&D and business development, including the acquisition of Pathline to expand Northeast market presence.
- CEO Tony Zook emphasized the company's patient-centric culture and commitment to community oncology, with plans to accelerate growth through new product launches and commercial expansion.

**【COO Business Update】**
- Clinical testing volumes increased 8% YoY, with NGS revenue growing 18%, driven by five new NGS products contributing 22% of Q1 clinical revenue.
- Launch of PanTracer LBx liquid biopsy in Q2 and upgraded NEO comprehensive NGS panel to PanTracer Tissue, enhancing community oncology testing options.
- Strategic partnership with Adaptive Biotechnologies to co-market MRD testing through the COMPASS menu, targeting academic medical centers.

**【CIO Product Development】**
- PanTracer LBx liquid biopsy completed analytical validation and entered Evaluation Assessment Program (EAP), with commercial launch planned for late Q2.
- Next-generation MRD development pipeline includes RaDaR 1.1 (analytical validation complete) and 2027-targeted next-gen MRD platform.
- Collaboration with Ultima Genomics to leverage UG 100 sequencing platform for advanced oncology testing solutions.

**【CFO Financial Review】**
- Q1 GAAP net income of $420 million and Non-GAAP EPS of $1.08, exceeding expectations.
- Adjusted gross margin improved 146 basis points to 47%, with $79 million in adjusted gross profit.
- Full-year 2025 guidance raised to $747-759 million in revenue, with Pathline expected to contribute $12-14 million in 2025.
- Non-clinical revenue decline of 15.8% YoY due to macroeconomic factors, offset by clinical growth and Pathline integration.

**【Q&A Key Insights】**
- Non-clinical business challenges include tariffs, NIH funding uncertainty, and pharma trial declines, but clinical growth remains strong.
- Pathline integration will drive 2026+ growth, with 2025 contributions offset by short-term EBITDA dilution.
- Sales force maturation (6-9 months to full productivity) aligns with Q4 2025/Q1 2026 revenue acceleration.
- MRD pipeline progress: RaDaR 1.1 operational readiness in 2025, next-gen MRD launch in 2027.
- Adaptive partnership to enhance COMPASS menu penetration in academic centers, with MRD testing synergy through single-sample workflow.

NeoGenomics (NEO)-29 Apr 25-2025 Q1 Earnings call transcript

- **Revenue Growth**: Q4 2024 revenue up 11% YoY to $172 million, driven by 24% NGS growth and 9% clinical volume increase.
- **Margin Expansion**: Adjusted gross margin 48% (highest in 5 years), with 240+ basis points improvement in 2024.
- **Long-Term Targets**: 12-13% annual revenue growth, 25%+ NGS growth, and 1 million patients annually by 2028.
- **New Products**: PanTracer liquid biopsy launch in H1 2025, upgraded Neo Comprehensive panel with HRD, and Adaptive MRD partnership.
- **MRD Litigation**: Trial in October 2025; focus on 1.1 adoption and next-gen MRD development.
- **Financial Health**: $387 million cash balance, $10 million positive cash flow, and plans to repay $201 million convertible notes in 2025.

**【CEO Summary Section】**
- Q4 2024 revenue reached $172 million, up 11% YoY, driven by 24% growth in NGS (34% full year growth) and 9% clinical testing volume increase. NGS now accounts for 30% of total revenue.
- Adjusted gross margin improved to 48% (highest in 5 years), with 240+ basis points of margin expansion in 2024. Adjusted EBITDA rose to $12 million (Q4) and $40 million (full year), up 38% YoY.
- Long-term financial targets: 12-13% annual revenue growth (excluding MRD), 25%+ NGS growth, and 100-150 basis points annual gross margin expansion.
- Launched PanTracer liquid biopsy in H1 2025 and upgraded Neo Comprehensive NGS panel with HRD. Expanded commercial team to 140 salespeople for community oncology penetration.
- Served 700,000 patients in 2024, targeting 1 million annually by 2028.

**【CFO Financial Commentary】**
- Full year 2024 revenue: $661 million (+12% YoY), with 12% clinical testing volume growth and 5% AUP increase. Adjusted EBITDA: $40 million (+36% YoY).
- Q4 2025 guidance: $735-745 million revenue (+11-13% YoY), $55-58 million adjusted EBITDA (+38-45% YoY). Q1 2025 revenue expected at 23% of full year, with H2 growth acceleration.
- Cash balance: $387 million (down 7% YoY) with $10 million positive cash flow from operations. Intends to repay $201 million convertible notes in May 2025.
- Sales & marketing expense: $22 million (+24% YoY) for commercial expansion. R&D: $8 million (+12% YoY) for product innovation.

**【Innovation & Commercial Strategy】**
- Launched exclusive MRD partnership with Adaptive Biotechnologies, combining clonoSEQ MRD assay with Neo's comprehensive testing. Expanded commercial team for community oncology penetration.
- PanTracer liquid biopsy to launch in H1 2025, targeting therapy selection in advanced solid tumors. Upgraded Neo Comprehensive panel with HRD for ovarian, breast, and prostate cancers.
- 2024 product launches: 13 new tests (7 in 2024), driving NGS growth and clinical menu expansion.

**【Q&A Highlights】**
- **MRD Litigation**: RaDaR 1.1 trial scheduled for October 2025. Adaptive partnership to strengthen MRD leadership. 2025 focus on 1.1 adoption and next-gen MRD development.
- **Pharma Business**: 2024 down 7% YoY due to lack of Q4 budget flush. 2025 expects modest growth in oncology data solutions and clinical trials.
- **PanTracer Strategy**: Launching in H1 2025 with 140+ salesforce. Targeting concurrent testing with solid tumor biopsies and community oncology adoption.
- **Gross Margin**: High-value tests (e.g., PanTracer) expected to drive 100-150 basis points annual margin expansion.
- **Long-Term Growth**: 12-13% revenue CAGR, 25%+ NGS growth, and 1 million patients served annually by 2028.

NEO

NEO fundamentals

Earnings Call

You can ask Aime